Clear Street on Beam Therapeutics Inc (BEAM): muted reaction is 'buying opportunity'

March 25, 2026 1:00 PM

Clear Street analyst Bill Maughan reiterated a Buy rating and $37.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM)The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found